FORM OF UNDERWRITING AGREEMENT QUARK PHARMACEUTICALS, INC. 5,000,000 Shares of Common StockUnderwriting Agreement • June 25th, 2007 • Quark Pharmaceuticals Inc • Pharmaceutical preparations • New York
Quark Pharmaceuticals, Inc., a California corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 5,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 750,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.
EXCLUSIVE LICENSE AGREEMENT “ISOLATION AND APPLICATION OF P53 INHIBITORS TO CONTROLLING TISSUE RESPONSE TO A VARIETY OF STRESSES AND FACILITATING ANTI- CANCER TREATMENT” (UIC Tech ID #CS01)Exclusive License Agreement • June 25th, 2007 • Quark Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This EXCLUSIVE LICENSE AGREEMENT is effective on the date last subscribed below (the “Effective Date”), and is by and between THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, a body corporate and politic of the State of Illinois (“UNIVERSITY”) with offices in Chicago, Illinois 60612, and QUARK BIOTECH, INC., a California corporation with principal offices at 1059 Serpentine Lane, Pleasanton, California 94566, (“QBI”).
